Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of VHL gene is the basis of familial inheritance of VHL syndrome. The protein is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein.
| Target |
VHL |
| Reactivity |
Human, Mouse |
| Host |
Rabbit |
| Clonality |
Polyclonal |
| Tested Applications |
WB, IHC, IF/ICC, FCM |
| Recommended dilutions |
Optimal dilutions/concentrations should be determined by the end user. |
| Immunogen |
KLH-conjugated synthetic peptide between 43-71 amino acids from the N-terminal region of human VHL. |
| Purification |
Purified through a protein G column, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS. |
| Isotype |
IgG |
| Conjugation |
Unconjugated |
| Storage |
Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Swiss Prot |
P40337
|
| NCBI Accession |
NP_000542.1
NP_937799.1
|
| Buffer |
PBS containing 0.09% sodium azide. |
| UNSPSC Code |
12352203 |
| Availability |
Shipped within 5-10 working days. |
| Note |
This product is for research use only. |